On April 16, 2026, the US Court of Appeals for the Federal Circuit issued a precedential decision in Teva Pharmaceuticals International GmbH v.

New data show early and sustained weight loss with atogepant, raising the possibility of metabolic benefits beyond migraine prevention.

The Federal Circuit recently clarified its written description jurisprudence concerning claims directed to methods of using a ...

Results provide evidence needed to challenge the step-through reimbursement requirements that have restricted Qulipta's ...

Findings showed meloxicam/rizatriptan statistically significantly improved migraine treatment response compared with prior oral CGRP inhibitor treatment. Topline data were announced from a phase 3 ...

Discover how "gepants" (CGRP inhibitors) are changing migraine care. Learn about their use for acute relief and prevention, ...

A statistically significant reduction in the mean number of monthly headache days (vs baseline) was observed for the CGRP-targeted therapies and propranolol ...

Calcitonin gene-related peptide (CGRP) inhibitors -- a group of drugs commonly used to treat migraine -- were associated with decreased rates of acne and rosacea compared with drugs that did not ...

The EMA has endorsed Aquipta, an oral CGRP receptor antagonist, after it showed superior pain relief vs placebo in treating migraine attacks in adults.

Ubrelvy is a prescription drug used to help treat migraine. It blocks a protein called calcitonin gene-related peptide (CGRP) from acting on your nervous system. Ubrelvy works rapidly, often in ...

SAN DIEGO -- Fremanezumab (Ajovy) cut monthly migraine days in children and adolescents with episodic migraine, according to the SPACE trial. The phase III study showed a reduction in monthly migraine ...